Brad Hively - 21 Aug 2026 Form 4 Insider Report for Starling Oncology, Inc. (STLN)

Reporting relationship: Director
Issuer ticker: STLN
Reported as of: 21 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Aug 2026, 17:11:12 UTC
Prior SEC filing: 29 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively

Key filing fact

Brad Hively filed Form 4 for Starling Oncology, Inc. (STLN) on 24 Aug 2026.

Key facts

This page summarizes Brad Hively's Form 4 filing for Starling Oncology, Inc. (STLN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2026, 17:11.

Change

Previous filing in this sequence was filed on 29 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891124 Primary reporting owner

Hively Brad

Relationship: Director
Address: C/O STARLING ONCOLOGY, INC., 18000 STUDEBAKER RD, SUITE 800, CERRITOS
Signature: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Brad Hively
Signature date: 24 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STLN transaction

Common Stock

Sale

Transaction value
Shares: -298,853
Change %: -42%
Price: $6.51^*
Shares after: 411,976
Date: 21 Aug 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.37 to $6.75 per share. Upon request by the SEC, the Issuer or a stockholder of the Issuer, complete information regarding the number of shares sold at each price within the range will be provided.